Market By Drug Class, Distribution Channel, End-user, And Geography | Forecast 2019-2028
Triton Market Research has concluded that the North America immunosuppressant drugs market will grow at a CAGR of 3.03% in the estimated years 2019-2028.
Report scope can be customized per your requirements. Request For Customization
The countries analyzed in this market include:
•          The United States
•          Canada
In Canada, approx. 2 million people are affected by autoimmune diseases. Around 50 types of known autoimmune diseases are said to affect around two million Canadians. Furthermore, according to the Arthritis Society, around 1 in 100 persons in the country is reported to have rheumatoid arthritis. Though, it mostly affects the middle-aged, it can also affect younger older people. Canada also has one of the highest rates of multiple sclerosis in the world. This condition is more prevalent in women.
Sjögren's syndrome is also one of the commonly occurring diseases in the country, and an estimated 430,000 people are said to live with the disease. Immunosuppressant drugs form a crucial part of the treatment for autoimmune disorders. Hence, the rising prevalence of autoimmune disorders in the country calls for an increasing adoption of immunosuppressant drugs. This is supporting the growth of the Canadian immunosuppressant drugs market.
Organ transplantation also significantly takes place in the nation. A total of 2,782 organ transplants were performed in 2018, according to the Canadian Organ Replacement Register (CORR). As per the data, out of the 762 deceased donors in the year, 71% were cases of donation after brain death (NDD), and 29% were cases of donation after cardio-circulatory death (DCD). There was an increase of 21% in NDD and an increase of 429% in DCD over a ten-year period in 2018. Immunosuppressant drugs are widely used to treat patients during these transplantation procedures. This is aiding the growth of the immunosuppressant drugs market in Canada over the forecasting period.
AbbVie Inc is a research-based biopharmaceutical company, which discovers, develops, manufactures, and sells a range of pharmaceutical products. The company's products are focused on treating chronic autoimmune diseases, among other serious health conditions. RINVOQ, HUMIRA, Upadacitinib, and Risankizumab are some of the immunosuppressant drugs it produces. The US-based company is headquartered in North Chicago, Illinois.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT
1. NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1.  ORGAN TRANSPLANTATION LEADS THE MARKET BY END-USER
2.2.2.  PHARMACEUTICAL INDUSTRY SHOWING GROWTH TRENDS
2.2.3.  IMPACT OF COVID-19 ON TRANSPLANT RECIPIENTS
2.3. EVOLUTION & TRANSITION OF IMMUNOSUPPRESSANT DRUGS
2.4. PORTER’S FIVE FORCE ANALYSIS
2.4.1.  THREAT OF NEW ENTRANTS
2.4.2.  THREAT OF SUBSTITUTE
2.4.3.  BARGAINING POWER OF SUPPLIERS
2.4.4.  BARGAINING POWER OF BUYERS
2.4.5.  THREAT OF COMPETITIVE RIVALRY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. MARKET DRIVERS
2.7.1.  DEMAND FROM ORGAN TRANSPLANTATION
2.7.2.  RISE IN THE NUMBER OF AUTOIMMUNE DISORDERS
2.8. MARKET RESTRAINTS
2.8.1.  SIDE-EFFECTS OF IMMUNOSUPPRESSANT DRUGS
2.9. MARKET OPPORTUNITIES
2.9.1.  DEMAND FROM EMERGING ECONOMIES
2.9.2.  EXPORTS OF DRUGS AND MEDICINE WORLDWIDE ON RISE
2.10. MARKET CHALLENGES
2.10.1. LACK OF AWARENESS ABOUT ORGAN DONATION
3. NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK – BY DRUG CLASS
3.1. CORTICOSTEROIDS
3.2. MONOCLONAL ANTIBODIES
3.3. CALCINEURIN INHIBITORS
3.4. MTOR INHIBITORS
3.5. OTHERS
4. NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK - BY DISTRIBUTION CHANNEL
4.1. HOSPITAL PHARMACIES
4.2. RETAIL PHARMACIES
4.3. ONLINE PHARMACIES
5. NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK - BY END-USER
5.1. ORGAN TRANSPLANTATION
5.2. AUTOIMMUNE DISORDERS
5.3. OTHERS
6. NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET – REGIONAL OUTLOOK
6.1. UNITED STATES
6.2. CANADA
7. COMPETITIVE LANDSCAPE
7.1. ABBVIE INC
7.2. ALLERGAN (ACQUIRED BY ABBVIE INC)
7.3. ASTELLAS PHARMA INC
7.4. BRISTOL-MYERS SQUIBB COMPANY
7.5. CIPLA LTD
7.6. DR REDDYS LABORATORIES LTD
7.7. F HOFFMANN-LA ROCHE LTD
7.8. GLAXOSMITHKLINE PLC
7.9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE)
7.10. JANSSEN PHARMACEUTICALS INC (JOHNSON & JOHNSON SERVICES INC)Â Â Â Â Â Â Â
7.11. MYLAN NV
7.12. NOVARTIS AG
7.13. PFIZER INC
7.14. SANOFI
7.15. VELOXIS PHARMACEUTICALS INC
8. METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY
TABLE 1: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS INDEX
TABLE 3: VENDOR SCORECARD
TABLE 4: SIDE-EFFECTS OF IMMUNOSUPPRESSANT DRUGS
TABLE 5: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
TABLE 6: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2019-2028 (IN $ MILLION)
TABLE 7: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (IN $ MILLION)
TABLE 8: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 9: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
FIGURE 1: EVOLUTION & TRANSITION OF IMMUNOSUPPRESSANT DRUGS
FIGURE 2: PORTER’S FIVE FORCE ANALYSIS
FIGURE 3: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CORTICOSTEROIDS, 2019-2028 (IN $ MILLION)
FIGURE 4: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
FIGURE 5: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CALCINEURIN INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 6: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 7: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 8: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 9: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 10: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY ONLINE PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 11: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TRANSPLANTATION, 2019-2028 (IN $ MILLION)
FIGURE 12: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY AUTOIMMUNE DISORDERS, 2019-2028 (IN $ MILLION)
FIGURE 13: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 14: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 15: UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 16: CANADA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)